Pivotal bioVenture Partners

Pivotal bioVenture Partners

MedCity News

AI powered and now publicly traded, Exscientia adds $464M to fuel drug R&D

neurons.AI

EQRx puts Exscientia’s AI on drug discovery duty to develop low-cost cancer drugs

neurons.AI

Exscientia Enters Binding Agreement to Acquire Allcyte

neurons.AI

British AI drug discovery startup Exscientia buys Austrian cancer cell screening company

Northstack

Oculis raises $57m Series C led by BVCF Management and Hyfinity Investments

Pulse 2.0

Exscientia Secures Investment Of Up To $525 Million

$225,000,000 Venture capital (Series D)
neurons.AI , neurons.AI

AI Drug Developer Exscientia Closes $525M in Financing

neurons.AI

Exscientia starts trials of first AI-derived cancer immunotherapy

$93,500,000 Venture capital (Series C)
FinSMEs , Xconomy

Bolt Biotherapeutics Raises $93.5M in Series C Financing

Xconomy

Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic

UKTN (UK Tech News)

Exscientia raises $60m Series C

the home of AI info

SRI International and Exscientia Enter Collaboration to Accelerate Drug Discovery Through …

$105,000,000 Venture capital (Series B)
FinSMEs

Akouos Raises $105M in Series B Financing

$110,000,000 Venture capital (Series D)
FinSMEs

SutroVax Raises $110M in Series D Financing

$105,000,000 Venture capital (Series B)
Pulse 2.0

Precision Genetic Medicine Company Akouos Secures $105 Million In Funding

the home of AI info

Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular ...

$67,000,000 Venture capital (Series A)
FinSMEs

Inozyme Pharma Raises $67M in Series A2 Financing

MedCity News

AI drug development partnership between GlaxoSmithKline, Exscientia yields first drug candidate

Silicon Canals

Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases

$26,000,000 Venture capital (Series B)
PE HUB , FinSMEs

Exscientia lands $26 mln Series B